COVID-19 Vaccine: Phase 1 clinical trial of DNA-based vaccine Covigenix VAX-001
$5,000,000.00
Grant Value
2020-21
Fiscal Year
Description
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001 vaccine candidate through Phase 1 clinical trials to establish its safety and immunogenicity in healthy adults.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Grant Details
Recipient
Entos Pharmaceuticals Inc.
Location
Edmonton, AB T5J 4P6
Agreement Details
Number: 956891
Reference: 172-2020-2021-Q2-956891
Timeline
Start: Sept. 1, 2020
End: March 31, 2021
Program
Industrial Research Assistance Program ? Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …
Sector
Professional, scientific and technical services (541710)
Your Contribution
Calculate how much you personally contributed to this grant through your taxes.
Calculate My Share